BP 013 - Brillian Pharma
Alternative Names: BP-013 - Brillian PharmaLatest Information Update: 10 Mar 2024
At a glance
- Originator Brillian Pharma
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Influenza virus infections
Most Recent Events
- 24 Jan 2024 Clinical trials in Influenza virus infections (In children) (PO), prior to January 2024 (Brillian Pharma pipeline, January 2024)
- 24 Jan 2024 Brillian Pharma plans to launch BP 012 in Influenza virus infections in China in the second quarter of 2026 (Brillian Pharma pipeline, January 2024)
- 24 Jan 2024 Brillian Pharma plans to launch BP 012 in Influenza virus infections in China in the third quarter of 2026 (Brillian Pharma pipeline, January 2024)